# ETON catalysts: Eton Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/eton/catalysts

> Eton Pharmaceuticals, Inc. (ETON) has 4 upcoming catalysts. The next is the ET-700 trial start, early 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ETON?

Eton Pharmaceuticals, Inc. (ETON) has 4 upcoming catalysts. The next is the ET-700 trial start, early 2027. Press release filed with the SEC (EX-99): "If pilot study results are successful, Eton anticipates initiating a pivotal clinical study in early 2027." [Calendar and source filings](https://sec-api.dev/companies/eton/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001437749-26-027672, https://www.sec.gov/Archives/edgar/data/1710340/000143774926027672/ex_974033.htm (retrieved 2026-11-12). Last confirmed 2026-08-13. Cite: https://sec-api.dev/companies/eton/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Eton Pharmaceuticals, Inc. |
| Ticker | ETON (Nasdaq) |
| SEC CIK | 1710340 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/eton |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 29, 2020 | [KHINDIVI® (hydrocortisone) FDA approval](https://sec-api.dev/pdufa/hydrocortisone) | ETON |  | completed, approved | "NDA213876 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20200929, review_priority STANDARD; sponsor_name ETON; product ALKINDI SPRINKLE (HYDROCORTISONE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213876%22)) |
| November 12, 2024 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774924034557/ex_728719.htm)) |
| Q1 2025 | [ET-600 NDA/BLA submission](https://sec-api.dev/pdufa/et-600) | ETON |  | scheduled | "If the study results are positive, Eton anticipates submitting an NDA for the product in the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774924034557/ex_728719.htm)) |
| February 6, 2025 | [ET-400 PDUFA date](https://sec-api.dev/pdufa/et-400) | ETON |  | scheduled | "DEER PARK, Ill., February 6, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the New Drug Application (NDA) for ET-400." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925002935/ex_775326.htm)) |
| February 28, 2025 | [ET-400 PDUFA date](https://sec-api.dev/pdufa/et-400) | ETON |  | scheduled | "In July, the FDA accepted Eton's NDA for ET-400, its proprietary patented formulation of hydrocortisone oral solution and assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774924034557/ex_728719.htm)) |
| March 18, 2025 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925008137/ex_786379.htm)) |
| Apr 2025 | [DESMODA (desmopressin) NDA/BLA submission](https://sec-api.dev/pdufa/desmopressin) | ETON |  | scheduled | "Company expects to submit New Drug Application (NDA) in April 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925007615/ex_788878.htm)) |
| April 28, 2025 | [ET-600 NDA/BLA submission](https://sec-api.dev/pdufa/et-600) | ETON | central diabetes insipidus | completed | "On April 28, 2025, the Company submitted an NDA to the FDA for ET-600, the Company's proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1710340/000143774925016475/eton20250331_10q.htm)) |
| May 13, 2025 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925016468/ex_811087.htm)) |
| May 13, 2025 | [ET-600 NDA/BLA submission](https://sec-api.dev/pdufa/et-600) | ETON |  | completed | "Announced positive pivotal clinical study results for ET-600 and submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925016468/ex_811087.htm)) |
| May 28, 2025 | [ET-400 PDUFA date](https://sec-api.dev/pdufa/et-400) | ETON |  | scheduled | "The new PDUFA goal date is May 28, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774925002935/eton20250205_8k.htm)) |
| May 28, 2025 | [KHINDIVI® (hydrocortisone) FDA approval](https://sec-api.dev/pdufa/hydrocortisone) | ETON |  | completed, approved | "DEER PARK, Ill., MAY 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Food and Drug Administration (FDA) approval of a New Drug Application (NDA) for KHINDIVI™ (hydrocortisone) Oral Solution as a replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925018698/ex_822865.htm)) |
| July 8, 2025 | [ET-600 NDA/BLA acceptance](https://sec-api.dev/pdufa/et-600) | ETON |  | completed | "On July 8, 2025, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Company's New Drug Application for ET-600, a proprietary patented formulation of desmopressin oral solution, was accepted for review by the Food and Drug Administration (FDA) and assigned a Prescription Drug User Fee Administration target action date of February 25, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774925022298/eton20250702_8k.htm)) |
| August 7, 2025 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925025438/ex_847128.htm)) |
| November 6, 2025 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925033616/ex_854696.htm)) |
| Q1 2026 | [DESMODA (desmopressin) NDA/BLA submission](https://sec-api.dev/pdufa/desmopressin) | ETON |  | scheduled | "We expect to submit the NDA shortly and have begun pre-launch commercial readiness activities in anticipation of a potential launch in the first quarter of 2026," said Sean Brynjelsen, CEO of Eton Pharmaceuticals." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925007615/ex_788878.htm)) |
| 1H 2026 | [KHINDIVI® (hydrocortisone) NDA/BLA submission](https://sec-api.dev/pdufa/hydrocortisone) | ETON |  | scheduled | "A pre-submission meeting with the FDA is scheduled for September, and the Company expects to file a supplement to the existing KHINDIVI New Drug Application (NDA) in the first half of 2026, which could allow for approval before the end of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925025438/ex_847128.htm)) |
| Feb 2026 | [ET-600 FDA approval](https://sec-api.dev/pdufa/et-600) | ETON |  | completed, approved | "In February 2026, the FDA approved the New Drug Application ("NDA") for ET-600 ("DESMODA™") and the Company launched DESMODA™ in March 2026 and was obligated to make a milestone payment of $250, which was paid in April 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1710340/000171034026000009/eton-20260930.htm)) |
| February 25, 2026 | [ET-600 NDA/BLA acceptance](https://sec-api.dev/pdufa/et-600) | ETON |  | scheduled | ""In addition to our strong commercial performance, we continued to advance our pipeline programs and received favorable news when our New Drug Application (NDA) for ET-600 was accepted for review by the FDA and assigned a Prescription Drug User Fee Act (PDUFA) date of February 25, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925033616/ex_854696.htm)) |
| February 25, 2026 | [DESMODA (desmopressin) PDUFA date](https://sec-api.dev/pdufa/desmopressin) | ETON |  | completed, approved | "On July 8, 2025, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Company's New Drug Application for ET-600, a proprietary patented formulation of desmopressin oral solution, was accepted for review by the Food and Drug Administration (FDA) and assigned a Prescription Drug User Fee Administration target action date of February 25, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774925022298/eton20250702_8k.htm)) |
| February 25, 2026 | [ET-600 PDUFA date](https://sec-api.dev/pdufa/et-600) | ETON |  | scheduled | "ET-600 NDA accepted for review, assigned PDUFA date of February 25, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925033616/ex_854696.htm)) |
| February 25, 2026 | [DESMODA (desmopressin) FDA approval](https://sec-api.dev/pdufa/desmopressin) | ETON |  | completed, approved | "DEER PARK, Ill., FEB 25, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Food and Drug Administration (FDA) approval of a New Drug Application (NDA) for DESMODA™ (desmopressin acetate) Oral Solution for the management of central diabetes insipidus, also known as arginine vasopressin deficiency (AVP-D), as antidiuretic replacement therapy for patients of all ages." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774926005537/ex_923604.htm)) |
| March 19, 2026 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774926009060/ex_889836.htm)) |
| April 27, 2026 | [ET-700 trial start](https://sec-api.dev/pdufa/et-700) | ETON | Wilson disease | completed | "DEER PARK, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the first patient has been dosed in a pilot clinical study assessing the efficacy of ET-700, the Company's proprietary, patent-pending formulation of extended-release zinc acetate under development for the treatment of Wilson disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774926013369/ex_940424.htm)) |
| May 14, 2026 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774926017063/ex_935862.htm)) |
| 2H 2026 | [ET-700 topline data readout](https://sec-api.dev/pdufa/et-700) | ETON |  | scheduled | "Topline study results are expected in the second half of 2026, and if positive, would lead to a pivotal clinical study in early 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774926017063/ex_935862.htm)) |
| August 13, 2026 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774926027672/ex_974033.htm)) |
| November 5, 2026 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000171034026000006/eton-2026q332026xexx991.htm)) |
| early 2027 | [ET-700 trial start](https://sec-api.dev/pdufa/et-700) | ETON |  | scheduled | "If pilot study results are successful, Eton anticipates initiating a pivotal clinical study in early 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774926027672/ex_974033.htm)) |
| March 29, 2027 | [Eton Pharmaceuticals, Inc. PDUFA date](https://sec-api.dev/companies/eton/catalysts) | ETON |  | scheduled | "An NDA with a March 29, 2027, PDUFA date is currently under FDA review and if approved, would add ages 6 to 11 to the product's label." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000171034026000006/eton-2026q332026xexx991.htm)) |
| May 28, 2027 | [KHINDIVI® (hydrocortisone) PDUFA date](https://sec-api.dev/pdufa/hydrocortisone) | ETON |  | scheduled | "KHINDIVI label expansion Prior Approval Supplement (PAS) accepted for review and assigned May 28, 2027 PDUFA date." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000171034026000006/eton-2026q332026xexx991.htm)) |
| 2H 2027 | [ASN-001 NDA/BLA submission](https://sec-api.dev/pdufa/asn-001) | ETON |  | scheduled | "Additionally, the Company will run a bioavailability bridging study for ASN-001 and the Company intends to submit the NDA upon completion of the study in the second half of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1710340/000143774926027684/eton20260630_10q.htm)) |

## Drugs

- [ASN-001](https://sec-api.dev/pdufa/asn-001): 
- [DESMODA (desmopressin)](https://sec-api.dev/pdufa/desmopressin): 
- [ET-400](https://sec-api.dev/pdufa/et-400): 
- [ET-600](https://sec-api.dev/pdufa/et-600): central diabetes insipidus
- [ET-700](https://sec-api.dev/pdufa/et-700): wilson disease
- [KHINDIVI® (hydrocortisone)](https://sec-api.dev/pdufa/hydrocortisone): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/eton/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ETON catalysts: Eton Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/eton/catalysts

```bibtex
@misc{secapidev_companies_eton_catalysts_20261116,
  title        = {ETON catalysts: Eton Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/eton/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_eton_catalysts_20261116","title":"ETON catalysts: Eton Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/eton/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
